Work

Supplementary Figure S2 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

Year: 2024

Type: supplementary-materials

Abstract: Supplementary Figure S2. Mean percent changes in S1P/C18:1 ratios following BXQ-350 treatment among patients for which samples were available.

DOI: 10.1158/1078-0432.27754932

Authors: Olivier Rixe, John L. Villano, Robert Wesolowski, Anne M. Noonan, Vinay K. Puduvalli, Trisha M. Wise-Draper, Richard Curry, Emrullah Yilmaz, Charlie Cruze, Besim Ogretmen, Gilles Tapolsky, Ray Takigiku

Language: English

Topic: Sphingolipid Metabolism and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4404423124

Cites:

Cited by:

Related to: 10